Company intelligence / Profile preview

Transformative

Boulder, Colorado, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Transformative Biotech develops and commercializes extraction-free, direct-to-PCR technologies and proprietary buffer systems for rapid, accurate molecular testing of infectious diseases and cancer, proven in over ~590,000–600,000 clinical diagnostic tests in a CLIA-certified lab during and after the COVID-19 pandemic.[1][5][6]

Therapeutic areas: OncologyInfectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Molecular Diagnostics

Partnerships

Summit Biolabs (acquisition of direct-to-PCR technologies and IP)[5][6]

Beyond the preview

Go deeper on Transformative.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transformative.

Explore the full profile